share_log

Novo-Nordisk A/S | 6-K: Articles of Association of Novo Nordisk A/S

SEC announcement ·  Mar 25 10:48
Summary by Moomoo AI
Novo Nordisk A/S, a foreign private issuer, has submitted a Form 6-K report to the United States Securities and Exchange Commission (SEC) on March 25, 2024. The report is in accordance with the rules 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The document filed by the Denmark-based pharmaceutical company indicates its compliance with the SEC's reporting requirements for foreign companies. Novo Nordisk's principal executive offices are located at Novo Allé 1, DK-2880, Bagsvaerd, Denmark.
Novo Nordisk A/S, a foreign private issuer, has submitted a Form 6-K report to the United States Securities and Exchange Commission (SEC) on March 25, 2024. The report is in accordance with the rules 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The document filed by the Denmark-based pharmaceutical company indicates its compliance with the SEC's reporting requirements for foreign companies. Novo Nordisk's principal executive offices are located at Novo Allé 1, DK-2880, Bagsvaerd, Denmark.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more